Results 11 to 20 of about 9,243 (198)
Response to allopurinol and febuxostat according to the fractional excretion of urate in men with gout [PDF]
Arthritis Care &Research, Accepted Article.Background Body mass index (BMI), glomerular filtration rate (GFR), and pretreatment urate levels have been reported to influence the urate‐lowering response to allopurinol. We investigated whether the fractional excretion of urate (FEUA) also modulates this response and relates to oxypurinol concentrations. We further evaluated its potential influence
Pascal Richette +27 more
wiley +3 more sources
Allopurinol Versus Febuxostat Use and the Risk of Cardiovascular Disease in People With Chronic Kidney Disease: A New-User Active Comparator Cohort Study. [PDF]
Nephrology (Carlton)This retrospective cohort study assessed the cardiovascular outcomes in people with chronic kidney disease who were newly prescribed allopurinol or febuxostat. ABSTRACT Aim Hyperuricaemia, a common comorbidity among people with chronic kidney disease, is widely treated with uric acid‐lowering agents such as allopurinol and febuxostat.
Inoue R +5 more
europepmc +2 more sources
Rheumatology and Therapy, 2023 Introduction This drug utilization study evaluated the impact of 2019 label changes on real-world febuxostat utilization among patients with gout. We describe the numbers and proportions of patients initiating febuxostat as new users (allopurinol-naïve ...
Alexandra Z. Sosinsky +4 more
doaj +1 more source
Saudi Journal of Kidney Diseases and Transplantation, 2023 Hyperuricemia is a risk factor for the progression of chronic kidney disease (CKD). We compared febuxostat versus allopurinol in the progression of CKD and hyperuricemia in 101 patients with Stage 3–4 CKD treated with febuxostat or allopurinol for at ...
Shankar Prasad Nagaraju +6 more
doaj +1 more source
Physiological Reports, 2021 We hypothesized acute moderate and drastic reductions in uric acid concentration exert different effects on arterial function in healthy normotensive and hypertensive adults.
Benjamin De Becker +9 more
doaj +1 more source
Frontiers in Pharmacology, 2022 Hyperuricemic nephropathy (HN) is a common clinical complication of hyperuricemia. The pathogenesis of HN is directly related to urea metabolism in the gut microbiota.
Zhen Xiong Zhao +8 more
doaj +1 more source
Febuxostat ameliorates secondary progressive experimental autoimmune encephalomyelitis by restoring mitochondrial energy production in a GOT2-dependent manner. [PDF]
PLoS ONE, 2017 Oxidative stress and mitochondrial dysfunction are important determinants of neurodegeneration in secondary progressive multiple sclerosis (SPMS). We previously showed that febuxostat, a xanthine oxidase inhibitor, ameliorated both relapsing-remitting ...
Josephe A Honorat +17 more
doaj +1 more source
The Xanthine Oxidase Inhibitor Febuxostat Suppresses Adipogenesis and Activates Nrf2
Antioxidants, 2023 Xanthine oxidoreductase (XOR) is a rate-limiting enzyme in purine catabolism that acts as a novel regulator of adipogenesis. In pathological states, xanthine oxidoreductase activity increases to produce excess reactive oxygen species (ROS).
Yoshiki Higa +21 more
doaj +1 more source
Impact of urate-lowering therapy on quality of life indicators in patients with gout
Современная ревматология, 2021 Gout can have a significant impact on the quality of life (QoL) of patients.Objective: to assess the dynamics of QoL indicators and the possibility of achieving the target level of uric acid (UA) in patients with gout on febuxostat therapy, with ...
M. N. Chikina +2 more
doaj +1 more source
Renal safety and urate-lowering efficacy of febuxostat in gout patients with stage 4–5 chronic kidney disease not yet on dialysis [PDF]
The Korean Journal of Internal Medicine, 2020 Background/Aims The safety and efficacy of febuxostat in patients with stage 4–5 chronic kidney disease (CKD) are still unclear owing to a lack of studies in these patients.
Sang-Hyon Kim +3 more
doaj +1 more source